← Eichor
Condition: Drug Resistant Bacterial Infection Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Drug Resistant Bacterial Infection

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Hotspots, Households and Hospitals: Enhanced Drug-resistant Tuberculosis Case Finding in Namibia
Phase N/A · 1 location(s) · University of Namibia · NCT05022238Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis
Phase 2/Phase 3 · 6 location(s) · University of California, San Francisco · NCT06441006Novel Triple-dose Tuberculosis Retreatment Regimen
Phase 3 · 1 location(s) · Institute of Tropical Medicine, Belgium · NCT04260477Pragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis
NA · 1 location(s) · University of California, San Francisco · NCT05553236Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of M
Phase 2 · 11 location(s) · Janssen Research & Development, LLC · NCT02354014Training Protocol on the Natural History of Tuberculosis
Phase N/A · 1 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT01212003A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)
Phase 2 · 17 location(s) · Locus Biosciences · NCT05488340A Study on Integrated Chinese and Western Medicine for Severe Pneumonia Caused by Multidrug-Resistant Gram-Negative Bact
NA · 1 location(s) · Henan University of Traditional Chinese Medicine · NCT07206745Meropenem vs Azithromycin Efficacy in Case XDR Enteric Fever
Phase 4 · 1 location(s) · Indus Hospital and Health Network · NCT07314281Bring BPaL2Me Trial Comparing Nurse-Led RR-TB Treatment to Physician-Led RR-TB Treatment
NA · 5 location(s) · Johns Hopkins University · NCT05671718Antibiotic Treatment for Pneumonia Caused by Stenotrophomonas Maltophilia in ICU Patients
Phase N/A · 1 location(s) · Centre Hospitalier de Saint-Denis · NCT07052604A PAN-USR TB Multi-Center Trial
Phase 3 · 3 location(s) · Shenzhen Third People's Hospital · NCT06905522Antimicrobial Therapy for Difficult-to-treat Pseudomonas Aeruginosa
Phase N/A · 48 location(s) · Centre Hospitalier Régional d'Orléans · NCT06738771An Adaptive Randomized Controlled Trial
NA · 1 location(s) · Columbia University · NCT05633056Linezolid Tolerance During the BPaL Regimen With Dosage Personalization Based on Therapeutic Drug Monitoring (TDM) Durin
Phase 4 · 1 location(s) · Marco Schiuma · NCT07477119FMT for the Decolonization of Carbapenem-resistant Enterobacteriaceae
Phase 1/Phase 2 · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT04759001A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis
Phase 3 · 35 location(s) · Otsuka Pharmaceutical Development & Commercialization, Inc. · NCT07209761Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis
NA · 1 location(s) · Albert Einstein College of Medicine · NCT06590428Further MT for Antibiotic-Resistant Bacterial Colonization
Phase 2 · 6 location(s) · Emory University · NCT05835206FMT to Eradicate Intestinal Colonization by Carbapenem-resistant Enterobacteriaceae
Phase 1/Phase 2 · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT05791396Helicobacter Pylori Local Prevalence and Antibiotic Resistance
Phase N/A · 1 location(s) · Technical University of Munich · NCT05561504
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.